Swash, Clinical trials in ALS: a review of the role of clinical and neurophysiological measurements. Amyotroph Lateral Scler Other Motor Neuron Disord, 2005. 6(4): p. 202-12.de Carvalho M, Costa J, Swash M. Clinical trials ALS: a review of the role of clinical and neurophysiological ...
About 20,000 people in the U.S. are living with ALS, also known as Lou Gehrig's disease. Patients with ALS have few options for treatment. Only two drugs have been approved by the Food and Drug Administration (FDA) for ALS, and both only modestly slow the course of the disease. Few...
Patients were asked to score functional domains of the ALS Functional Rating Scale (ALSFRS-R) and rank the order of importance of each domain. Two weeks after the initial invite, the questionnaire was repeated to evaluate test-retest reliability. Vital status was extracted from the municipal ...
Percentage of clinical trials in which each of the various hypotheses for AD were tested up to 2019. The amyloid hypothesis was the most heavily tested (22.3% of trials); the neurotransmitter hypothesis was the second most tested (19.0% of trials); the percentage of trials that tested the ta...
the simulation of future ALS clinical trials, the verification of previously proposed predictive features, the discovery of novel predictors of ALS progression and survival, the newly identified stratification of patients based on their disease progression profiles, and the development of tools for better...
de Carvalho, M. & Swash, M. Can selection of rapidly progressing patients shorten clinical trials in amyotrophic lateral sclerosis?Arch. Neurol.63, 557–560 (2006). ArticlePubMedGoogle Scholar Moore, D. H. II & Miller, R. G. Improving efficiency of ALS clinical trials using lead-in design...
focused on developing plans to enroll more participants from underrepresented racial and ethnic populations into US clinical trials. Adding to the regulatory push, the omnibus spending bill was enacted (Public Law 117-328) requiring diversity action plans for the clinical trials used by the...
The level of the polyamines spermidine and spermine were increased in red blood cells in both patients with ALS and patients with Parkinson's disease, suggesting that polyamines may have a role for the neurodegenerative process. Polyamines in spinal cord were of the same level in the patients ...
for this common familial form of ALS (fALS), with an international clinical trial already under way (clinicaltrials.gov: NCT03626012)4,5. But for most patients with ALS, who have sporadic disease (sALS), these discoveries have yet to translate into meaningful therapies. A major barrier has ...
Prof. Michal Schwartz from Weizmann Institute and founder of ImmunoBrain Checkpoint says her team finds brain needs immune system for its protection and repair; trials to begin in 8 centers in Netherlands, UK and Israel